江苏鱼跃医疗设备股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | 2023 年 1-6 | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用 | 占用方与 上市公司 | 上市公司核 | 2023 年期初 | 月占用累计 | 2023 年 6 月占用资 | 1- | 2023 年 1-6 | 2023 年 6 | 占用形成 | | | 非经营性资金占用 | 方名称 | | 算的会计科 | 占用资金余 | 发生金额 | | | 月偿还累计 | 月 30 日占 | 原因 | 占用性质 | | | | 的关联关 | 目 | 额 | （不含利 | 金的利息 | | 发生金额 | 用资金余额 | | | | | | 系 | | | 息） | （如有） | | | | | | | 控股股东、实际控 制人及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-029 江苏鱼跃医疗设备股份有限公司 关于 2021 年度第一期员工持股计划第二个锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗"或"公司"）于 2021 年 6 月 17 日召开第五届董事会第八次临时会议和第五届监事会第四次临时会议，于 2021 年 7 月 5 日召开 2021 年第一次临时股东大会，审议通过了《公司 2021 年度第一期员工持 股计划（草案）及其摘要》等相关议案。具体内容详见公司于 2021 年 6 月 18 日和 2021 年 7 月 6 日披露在《证券时报》及巨潮资讯网（www.cninfo.com.cn）上的相关公告。 公司 2021 年度第一期员工持股计划（以下简称"本次员工持股计划"）第二个锁定 期于 2023 年 8 月 26 日届满，根据中国证监会《关于上市公司实施员工持股计划试点的 指导意见》、《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 的相关规定，现将本次员工 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-028 江苏鱼跃医疗设备股份有限公司 关于子公司土地收储有关事项进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易情况概述 为加快推进旧区改造，实施城市规划，上海市虹口区土地发展中心（以下简 称"虹口土发中心"）对江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗" 或"公司"）子公司上海医疗器械（集团）有限公司手术器械厂（以下简称"上 手厂"）名下的上海市虹口区粤秀路 351 号地块相关国有土地使用权、房屋、地 上及地下建筑物/构筑物实施收储（以下简称"本次收储"或"本次交易"）。 公司、上手厂于 2022 年 12 月 9 日与虹口土发中心就本次收储签订《收购粤 秀路 351 号地块国有土地使用权补偿合同》（以下简称"收购土地使用权补偿合 同"），约定收储土地面积 38,490 平方米，建筑面积 29,457 平方米，搭建面积 5,574.7 平方米，约定综合补偿金额为人民币 999,869,000.00 元（大写：人民币玖 亿玖仟玖佰捌拾陆万玖仟元整）。 截至 2022 年 ...

证券代码：002223 证券简称：鱼跃医疗 江苏鱼跃医疗设备股份有限公司投资者关系活动记录表 编号：2023-5-12 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 活动参与人员 | 线上参与 2022 年度网上业绩说明会的投资者 | | 时间 | 2023 年 5 月 12 日 15:00-17:00 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | 上市公司接待人员姓 | 董事长/总经理 吴群 | | 名 | 副总经理/首席财务官 张勇 | | | 财务负责人 刘丽华 | | | 独立董事 万遂人 | | | 董事/董事会秘书 王瑞洁 | | | 公司于 2023 年 5 月 12 日 15:00-17:00，通过深圳市全景网络有限公司提供的网上平 | | | 台（https://ir.p5w.net）采用网络远程形式举办 2022 年度公司业绩说明会，投资者对 | ...

江苏鱼跃医疗设备股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布《2022 年年度报告》全文及摘要，为广大投资者能进一步了解公司经营 情况，公司定于 2023 年 5 月 12 日（星期五）下午 15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长/总经理吴群先生、公司副 总经理/首席财务官张勇先生、公司财务负责人刘丽华女士、公司独立董事万遂 人先生、公司董事/董事会秘书王瑞洁女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 11 日（星期四）15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入 问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问 题进行回答。欢迎广大投资者积极参与本次业绩说明会。 证券代码 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,702,565,759.46, representing a 48.41% increase compared to CNY 1,821,064,321.07 in the same period last year[4] - Net profit attributable to shareholders was CNY 713,524,000.08, up 53.79% from CNY 464,412,551.72 year-on-year[4] - The net profit after deducting non-recurring gains and losses reached CNY 703,197,797.43, marking a 79.18% increase from CNY 392,890,525.95 in the previous year[4] - Basic earnings per share rose to CNY 0.7186, reflecting a 55.21% increase from CNY 0.4634 in the previous year[4] - The operating profit for Q1 2023 was CNY 865.19 million, significantly higher than CNY 545.42 million in Q1 2022, reflecting a growth of 58.6%[16] - The company reported a total comprehensive income of CNY 707.99 million for Q1 2023, compared to CNY 459.90 million in Q1 2022, an increase of 54.0%[17] Cash Flow and Assets - The net cash flow from operating activities was CNY 815,331,594.82, a significant increase of 97.94% compared to CNY 411,916,788.95 in the same quarter last year[4] - Cash and cash equivalents in current assets were CNY 641,237,591.56, a significant increase from CNY 81,746,236.98 in the previous period[14] - The cash and cash equivalents at the end of Q1 2023 were CNY 3.64 billion, a decrease from CNY 2.45 billion at the end of Q1 2022[19] - The company experienced a net cash outflow from investing activities of CNY 1.55 billion in Q1 2023, compared to an outflow of CNY 471.16 million in Q1 2022[19] - Total assets at the end of the reporting period were CNY 15,416,068,458.54, a 2.06% increase from CNY 15,095,211,328.39 at the end of the previous year[4] Liabilities and Equity - Total liabilities decreased to CNY 4,635,568,244.60 from CNY 5,039,109,299.59, indicating a reduction of 8.0%[14] - The company's total equity increased to CNY 10,780,500,213.94, up from CNY 10,066,485,523.85, representing a growth of 7.1%[14] - The total liabilities at the end of Q1 2023 were CNY 4.76 billion, reflecting an increase from CNY 3.12 billion at the end of Q1 2022[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 77,627, with the largest shareholder, Jiangsu Yuyue Technology Development Co., holding 245,983,450 shares, representing 24.54% of the total shares[9] - Jiangsu Yuyue Technology Development Co. holds a total of 245,983,450 shares, accounting for 24.54% of the company's total equity, with 21 million shares pledged and 2 million shares frozen[10] - The top ten shareholders include both individual and institutional investors, with the largest individual shareholder, Wu Guangming, holding 10.32% of the shares[9] Expenses and Costs - Total operating costs for Q1 2023 were CNY 1,848,004,283.26, up 37.7% from CNY 1,342,363,107.41 in Q1 2022[15] - The company experienced a 51.62% increase in selling expenses, attributed to expanded sales efforts and increased advertising expenditures[7] - Research and development expenses amounted to CNY 135,236,278.10, slightly increasing from CNY 129,004,920.41 year-over-year[15] Regulatory and Market Developments - The company faced an administrative penalty of RMB 2.7 million from the Zhenjiang Market Supervision Administration for regulatory violations[11] - The company received a medical device registration certificate for its 14-day non-calibrated Continuous Glucose Monitoring (CGM) system on March 15, 2023, marking a significant breakthrough in diabetes care solutions[11] - The company aims to enhance its market presence by leveraging the advantages of its new CGM product in clinical effectiveness, comfort, portability, safety, and digital management[11] Asset Management - The company reported cash and cash equivalents of approximately RMB 3.72 billion, a decrease from RMB 4.84 billion in the previous period[12] - Accounts receivable increased to RMB 809.65 million from RMB 646.77 million, indicating a growth of approximately 25.1%[12] - Inventory decreased to RMB 1.32 billion from RMB 1.51 billion, reflecting a decline of about 12.4%[12] - The company’s financial assets held for trading increased to approximately RMB 2.94 billion from RMB 2.51 billion, showing a growth of about 16.9%[12] Impairment and Goodwill - The company reported a 9236.62% increase in asset impairment losses, mainly due to increased inventory write-downs and impairment provisions for long-term assets[8] - The company’s goodwill stood at CNY 1,109,753,277.27, showing a slight increase from CNY 1,109,596,428.05 year-over-year[14]

Financial Performance - The company's operating revenue for 2022 was CNY 7,101,679,159.74, representing a 3.01% increase compared to CNY 6,894,308,112.28 in 2021[6]. - The net profit attributable to shareholders for 2022 was CNY 1,595,037,435.14, an increase of 7.60% from CNY 1,482,421,641.48 in 2021[6]. - The net cash flow from operating activities increased by 91.88% to CNY 2,304,919,408.76 in 2022, compared to CNY 1,201,201,633.89 in 2021[6]. - The total assets at the end of 2022 reached CNY 15,095,211,328.39, a 25.82% increase from CNY 11,997,858,899.82 at the end of 2021[6]. - The net assets attributable to shareholders increased by 19.20% to CNY 9,860,018,658.01 at the end of 2022, compared to CNY 8,272,114,352.19 at the end of 2021[6]. - The basic earnings per share for 2022 was CNY 1.61, an increase of 8.05% from CNY 1.49 in 2021[6]. - The company achieved total revenue of 7.102 billion yuan in 2022, representing a year-on-year growth of 3.01%[52]. - Operating profit reached 1.842 billion yuan, an increase of 9.11% compared to the previous year[52]. - The company reported a total revenue of 3.740 billion in 2022, maintaining a steady performance compared to previous years[116]. Dividend Policy - The company reported a cash dividend of 6 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares (including tax), amounting to a total cash dividend of approximately 612.71 million CNY for the year[142][143]. - The company reported a total distributable profit of approximately 5.84 billion CNY, with cash dividends accounting for 100% of the profit distribution[143]. - The estimated total cash dividend for 2022 is RMB 597,748,057.20, based on the adjusted total share capital[146]. - The company has no plans for stock dividends, focusing solely on cash dividends for shareholders[142]. Market Position and Growth Opportunities - The company is positioned in a growing medical device market, driven by factors such as GDP growth, aging population, and increasing healthcare demands[34]. - The company anticipates continued growth opportunities in the medical device sector, supported by favorable government policies and increasing R&D investments[35]. - The domestic market for home respiratory devices is still in the development stage, with a low penetration rate, but is expected to grow significantly due to increasing chronic respiratory disease patients and enhanced health management awareness[38]. - The number of diagnosed diabetes patients in China reached 116 million in 2019, projected to reach 200 million by 2030, driving demand for blood glucose monitoring devices[39]. - The company is focusing on expanding its product lines and enhancing its research and development capabilities in the medical device sector[119]. Research and Development - The company has established R&D centers in multiple locations, including Germany and Taiwan, to enhance innovation capabilities[51]. - Research and development expenses increased by 16.62% to ¥496 million, reflecting the company's commitment to innovation[57]. - The company is focusing on R&D for key technologies in diagnostic test strips, which will enhance its product competitiveness in the market[69]. - The company is enhancing its product competitiveness through technology upgrades and optimization of existing blood glucose test strips, including the dehydrogenase and oxidase types, to meet new national standards[70]. - R&D investment increased to ¥496.40 million in 2022, up 16.62% from ¥425.67 million in 2021, representing 6.99% of total revenue[74]. Corporate Governance - The company has maintained a strong governance structure, ensuring compliance with relevant laws and regulations, and has no significant discrepancies in governance practices[111]. - The company operates independently from its controlling shareholders in terms of business, assets, personnel, and finances, ensuring complete operational autonomy[112]. - The company has established independent personnel management systems and does not allow interference from controlling shareholders in its management decisions[113]. - The board of directors includes a diverse group of members, with the chairman and general manager holding 77,389,840 shares[115]. - The company is committed to transparency, with all board meeting resolutions disclosed in a timely manner[131]. Employee Welfare and Training - The total number of employees at the end of the reporting period was 6,362, with 2,899 in the parent company and 3,463 in major subsidiaries[139]. - The employee composition includes 2,664 production personnel, 1,482 sales personnel, and 1,137 technical personnel, reflecting a diverse skill set[139]. - The company emphasizes a diverse training program for employees, including overseas training and specialized courses from prestigious institutions[141]. - The company has established a comprehensive labor contract system and provides various social insurance benefits to all employees[161]. - The company emphasizes employee welfare, organizing various recreational activities and providing support for employees in need through the "Yuyue Love Fund"[162]. Strategic Partnerships and Acquisitions - The company has completed several acquisitions, including Zhejiang Kailite and Shanghai Zhongyou, to expand its product offerings[50]. - The company is actively seeking strategic partnerships for international market expansion, tailoring its approach to different countries' medical needs and cultural contexts[102]. - The company has completed the acquisition of a local medical device firm, enhancing its product portfolio and market presence[126]. - Jiangsu Yuyue plans to enter new markets, targeting Southeast Asia and Europe, with an expected market entry by Q3 2023[126]. Environmental Responsibility - The company actively promotes green practices and has implemented measures to reduce carbon emissions and improve resource efficiency[157]. - The company is committed to environmental responsibility, promoting energy efficiency and waste management, and has implemented paperless office practices[163]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[157]. Financial Management - The company is enhancing its cash flow management and increase the proportion of prepayment and cash delivery models in its operations[74]. - The company is actively managing its financial assets with no reported impairments, reflecting effective risk management practices[194]. - The company has not engaged in any major related party transactions during the reporting period[180]. - The company has no non-operating fund occupation by controlling shareholders or other related parties[172].

Group 1: Strategic Partnerships and Collaborations - The company signed a framework agreement with Alibaba Health for comprehensive cooperation in the smart health hardware sector, focusing on user-centered health data management [3] - The collaboration aims to provide health management and chronic disease management data products and services to individuals, medical institutions, and pharmaceutical companies [3] - The company has established regular communication with Alibaba Health to coordinate specific projects and collaborations [3] Group 2: Mergers and Acquisitions - Mergers and acquisitions are a key strategic direction for the company, focusing on areas related to high-value consumables, home medical products, and hospital resources [4] - The company aims to pursue acquisition targets that align with its strategic development and enhance its competitive edge [4] - Future acquisitions may include hospitals if they can help overcome institutional barriers and promote clinical applications [5] Group 3: Product and Service Integration - The company has a strong chronic disease management product line and extensive resources connecting hospitals, doctors, and patients [4] - The subsidiary, Yiyun Health, serves as a direct link between products and medical resources, enhancing the integration of smart hardware with healthcare services [4] - The focus is on leveraging top-tier medical professionals to provide high-quality healthcare services through the platform [5] Group 4: Internationalization Strategy - The company is pursuing an internationalization strategy, with efforts to establish its own brand rather than relying solely on OEM exports [6] - It has teams and subsidiaries in Southeast Asia and South Africa, promoting its brand locally with positive results [6] - The company acknowledges that building a brand is a long-term endeavor that requires persistence and may involve sacrificing short-term OEM orders [6] Group 5: Financial Considerations - Initial investments in Yiyun Health are limited to 5 million yuan, accounting for 10% of the company's early-stage funding [5] - The major shareholder is committed to protecting the listed company and will consider injecting Yiyun's profits into the company once it becomes profitable [5] - The company is cautious about the complexities of hospital management and does not plan to acquire a large number of hospitals [5]

Sales Channels and Strategies - The company has two main sales channels: hospital clinical sales for high-value consumables and home medical devices sold through pharmacies and e-commerce [1] - E-commerce has rapidly developed over the past two years, becoming a significant growth point for the company's external sales channels [1] - The company has strengthened control over terminal sales, including personnel deployment, sales expenses, and brand promotion [1] E-commerce Impact - The impact of online product sales prices on offline prices is minimal due to strict product differentiation and price control across various platforms [2] - New models are specifically designed for online sales, avoiding price conflicts with offline products [2] Medical Cloud Development - The medical cloud platform, launched in May, has seen significant growth, with user numbers increasing geometrically after the introduction of excellent physicians [2] - The focus is on user tracking and maintenance to ensure high-quality service, with plans to expand chronic disease management services [2] Acquisition and Operational Efficiency - Following the acquisition of Shanghai Medical Device Group, there have been no major changes to the management team [3] - Future efforts will focus on cost reduction, employee incentives, and product structure enhancement to improve overall competitiveness [3] New Product Development - The company is cautious about promoting new products, including the recently launched sleep apnea machine, which utilizes leading international technology [3] - The product is expected to grow alongside the market, targeting both personal and medical fields [3] Non-Public Offering Progress - The company's non-public offering application was submitted in August and has been accepted by the China Securities Regulatory Commission, with no recent updates available [3]